A Review of Cannabis in Chronic Kidney Disease Symptom Management Claudia Ho, Dan Martinusen, and Clifford Lo2,4,5 Canadian Journal of Kidney Health and Disease, 2019, Volume 6, 1–14 DOI: 10.1177/2054358119828391 journals.sagepub.com/home/cjk Abstract Purpose of Review : Physical and psychological symptom burden in patients with advanced chronic kidney disease (CKD) is significantly debilitating; yet, it is often inadequately treated. Legalization of cannabis in Canada may attract increasing interest from patients for its medical use in refractory symptom management, but its indications and long-term adverse health impacts are poorly established, creating a challenge for clinicians to support its use. In this review, we summarize key clinical studies and [...]
Lire la suiteEffects of Cannabidiol and a Novel Cannabidiol Analog against Tactile Allodynia in a Murine Model of Cisplatin-Induced Neuropathy: Enhanced Effects of Sub-Analgesic Doses of Morphine Hannah Marie Harris, Waseem Gul, Mahmoud A. ElSohly, Kenneth J. Sufka Medical Cannabis and Cannabinoids, 2018, 1, 54–59 Preclinical Science and Clinical Studies – Research Article DOI: 10.1159/000489077 Abstract Objective : This research examined whether a cannabidiol (CBD)-opioid pharmacotherapy could attenuate cisplatin-induced tactile allodynia. Methods : Mice (C57BL/6) were given 6 doses of 2.3 mg/kg cisplatin intraperitoneally (IP) on alternating days to induce tactile allodynia as quantified using an electric von Frey (eVF). Test groups in Experiment 1 received either vehicle, 0.1 [...]
Lire la suiteThe Use of Cannabis for Headache Disorders Bryson C. Lochte, Alexandre Beletsky, Nebiyou K. Samuel, Igor Grant Cannabis and Cannabinoid Research, 2017, Vol. 2, No 1., 61-71 https://doi.org/10.1089/can.2016.0033 Abstract Headache disorders are common, debilitating, and, in many cases, inadequately managed by existing treatments. Although clinical trials of cannabis for neuropathic pain have shown promising results, there has been limited research on its use, specifically for headache disorders. This review considers historical prescription practices, summarizes the existing reports on the use of cannabis for headache, and examines the preclinical literature exploring the role of exogenous and endogenous cannabinoids to alter headache pathophysiology. Currently, there is not [...]
Lire la suiteA Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain Griffin A. TYREE, Reith SARKAR, Brandon K. BELLOWS, Ronald J. ELLIS, Joseph HAMPTON ATKINSON, Thomas D. MARCOTTE, Mark S. WALLACE, Igor GRANT, Yuyan SHI, James D. MURPHY, and David J. GRELOTTI Cannabis and Cannabinoid Research, Volume 0, Number 0, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0027 Abstract Background : A recent meta-analysis affirmed the benefit of medicinal cannabis for chronic neuropathic pain, a disabling and difficult-to-treat condition. As medicinal cannabis use is becoming increasingly prevalent among Americans, an exploration of its economic feasibility is warranted. We present this cost-effectiveness analysis of adjunctive [...]
Lire la suiteBibliographie CANNABINOÏDES et Douleurs Neuropathiques Dr Christian SUEUR, GRECC, octobre 2018. ABRAMS D.I. et al. : Short-term effects of cannabinoids in patients with HIV-1 infection : a randomized, placebo-controlled clinical trial, Annals of Internal Medicine, 2003, 139, 4, 258-266. ABRAMS D.I., JAY C.A., SHADE S.B. et al. : Cannabis in painful HIV-associated sensory neuropathy : a randomized placebo-controlled trial, Neurology, 2007, 68, 515-521. DOI : 10.1212/01.wnl.0000253187.66183.9c ABRAMS D.I., COUEY P., SHADE S.B., KELLY M.E., BENOWITZ N.L. : Cannabinoid-Opioid Interaction in chronic Pain, Clinical Pharmacology & Therapeutics, 2011, 90, 6, 844-51. DOI : 10.1038/CLPT.2011.188 AGGARWAL S.K., CARTER G.T., SULLIVAN M.D. et al. : Medicinal use of cannabis in the United [...]
Lire la suite